title: CaMKIIalpha interacts with M4 muscarinic receptors to control receptor and psychomotor function.
abstract: Muscarinic acetylcholine receptors (mAChRs) are widely expressed in the mammalian brain and are essential for neuronal functions. These receptors are believed to be actively regulated by intracellular signals, although the underlying mechanisms are largely unknown. In this study, we show that Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) binds directly and selectively to one of five mAChR subtypes, M4 receptors (M4Rs), at their C-terminal regions of second intracellular loops. This binding relies on Ca(2+) activation of the kinase and leads to the phosphorylation of M4Rs at a specific threonine site (Thr145). Complementary in vivo studies in rat striatal neurons enriched with M4Rs confirm that rising Ca(2+) recruits CaMKIIalpha to M4Rs to potentiate receptor signalling, which controls behavioural sensitivity to dopamine stimulation in an activity-dependent manner. Our data identify a new model of protein-protein interactions. In a Ca(2+)-sensitive manner, CaMKIIalpha regulates M4R efficacy and controls the acetylcholine-dopamine balance in the basal ganglia and also the dynamics of movement.
authors.affiliation: Department of Basic Medical Science, University of Missouri-Kansas City, Kansas City, MO, USA.
authors.forename: Ming-Lei
authors.initials: ML
authors.lastname: Guo
authors.forename: Eugene E
authors.initials: EE
authors.lastname: Fibuch
authors.forename: Xian-Yu
authors.initials: XY
authors.lastname: Liu
authors.forename: Eun Sang
authors.initials: ES
authors.lastname: Choe
authors.forename: Shilpa
authors.initials: S
authors.lastname: Buch
authors.forename: Li-Min
authors.initials: LM
authors.lastname: Mao
authors.forename: John Q
authors.initials: JQ
authors.lastname: Wang
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000378:metabolism*; D003042:Cocaine / Q000494:pharmacology; D003342:Corpus Striatum / Q000502:physiology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D008124:Locomotion / Q000187:drug effects; D009474:Neurons / Q000502:physiology; D010766:Phosphorylation; D011485:Protein Binding; D054730:Protein Interaction Domains and Motifs; D025941:Protein Interaction Mapping; D051381:Rats; D043588:Receptor, Muscarinic M4 / Q000378:metabolism*
chemical_list: D018765:Dopamine Uptake Inhibitors; D043588:Receptor, Muscarinic M4; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D003042:Cocaine; D002118:Calcium
references.citation: Nat Rev Neurosci. 2002 Mar;3(3):175-90
references.pmid: 11994750
references.citation: J Neurosci. 2004 Sep 29;24(39):8394-8
references.pmid: 15456810
references.citation: Eur J Pharmacol. 1993 Jul 20;238(2-3):377-81
references.pmid: 8405105
references.citation: Proc Natl Acad Sci U S A. 1984 Feb;81(3):945-9
references.pmid: 6583689
references.citation: Mol Pharmacol. 1993 Feb;43(2):149-57
references.pmid: 8429821
references.citation: J Biol Chem. 1990 Jul 5;265(19):11213-9
references.pmid: 2162839
references.citation: Eur J Neurosci. 2010 Jan;31(1):14-28
references.pmid: 20092552
references.citation: Pharmacol Ther. 2008 Feb;117(2):232-43
references.pmid: 18082893
references.citation: J Neurochem. 1998 Oct;71(4):1733-41
references.pmid: 9751209
references.citation: Crit Rev Neurobiol. 1996;10(1):69-99
references.pmid: 8853955
references.citation: Science. 1992 May 22;256(5060):1199-202
references.pmid: 1317063
references.citation: Prog Neurobiol. 1998 Dec;56(5):507-40
references.pmid: 9775402
references.citation: Nat Neurosci. 2009 May;12(5):602-10
references.pmid: 19349975
references.citation: Synapse. 1997 Dec;27(4):357-66
references.pmid: 9372558
references.citation: Biochem J. 2004 Feb 15;378(Pt 1):1-16
references.pmid: 14653781
references.citation: J Neurosci. 1991 Oct;11(10):3218-26
references.pmid: 1941081
references.citation: Neuron. 2006 Dec 7;52(5):897-909
references.pmid: 17145509
references.citation: Eur J Pharmacol. 2002 Jul 19;448(2-3):105-11
references.pmid: 12144929
references.citation: Annu Rev Biochem. 2002;71:473-510
references.pmid: 12045104
references.citation: Trends Neurosci. 2007 May;30(5):228-35
references.pmid: 17408758
references.citation: Neuron. 2009 Feb 12;61(3):425-38
references.pmid: 19217379
references.citation: Neurochem Res. 2006 Apr;31(4):555-61
references.pmid: 16758365
references.citation: Pharm Res. 2006 Apr;23(4):647-53
references.pmid: 16552497
references.citation: J Neurosci. 1998 Dec 1;18(23):10207-18
references.pmid: 9822774
references.citation: Mol Biol Cell. 2007 Dec;18(12):5024-33
references.pmid: 17942605
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6245-7
references.pmid: 10841527
references.citation: J Neurochem. 2009 Jun;109(5):1193-202
references.pmid: 19457160
references.citation: Nature. 2001 Jun 14;411(6839):801-5
references.pmid: 11459059
references.citation: Synapse. 1989;3(1):48-54
references.pmid: 2537539
references.citation: J Pharmacol Exp Ther. 1990 Jun;253(3):987-92
references.pmid: 1972756
references.citation: FEBS Lett. 1994 Sep 19;352(1):91-4
references.pmid: 7925952
references.citation: Science. 2002 Oct 25;298(5594):846-50
references.pmid: 12399596
references.citation: J Neurosci. 1994 May;14(5 Pt 2):3351-63
references.pmid: 8182478
references.citation: Pharmacol Ther. 2008 Jul;119(1):33-43
references.pmid: 18558434
references.citation: Curr Opin Neurobiol. 2004 Jun;14(3):318-27
references.pmid: 15194112
references.citation: Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10483-8
references.pmid: 10468635
references.citation: J Comp Neurol. 2001 Jun 11;434(4):445-60
references.pmid: 11343292
references.citation: Psychopharmacology (Berl). 1994 Jul;115(3):297-304
references.pmid: 7871068
references.citation: J Pharmacol Exp Ther. 1989 Jan;248(1):171-5
references.pmid: 2563286
references.citation: Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3239-44
references.pmid: 10077668
references.citation: Trends Neurosci. 1994 Jun;17(6):228-33
references.pmid: 7521083
references.citation: Brain Res. 2001 Mar 9;894(1):12-20
references.pmid: 11245810
references.citation: J Biol Chem. 1998 Feb 6;273(6):3166-72
references.pmid: 9452427
references.citation: J Neurochem. 2008 Dec;107(5):1188-95
references.pmid: 18957051
references.citation: FASEB J. 2004 Sep;18(12):1410-2
references.pmid: 15231726
references.citation: Biochem Biophys Res Commun. 2005 Jul 29;333(2):390-5
references.pmid: 15950946
references.citation: Eur J Pharmacol. 1987 Jul 23;139(3):345-8
references.pmid: 3666010
references.citation: Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10890-5
references.pmid: 9724800